Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 17/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21193554 | 0.88 | GBA1 (0.66) | GBA1 | |
| SCHEMBL18153268 | 0.84 | HRH4 (0.41) | GBA1LMNAHRH4 | |
| SCHEMBL18153279 | 0.81 | GPR119 (0.56) | GBA1ALDH1A1LMNAHRH4 | |
| SCHEMBL9884923 | 0.79 | HRH4 (0.64) | HRH4 | |
| SCHEMBL11963431 | 0.79 | GBA1 (0.42) | GBA1ALDH1A1LMNA | |
| SCHEMBL3405363 | 0.79 | CRHBP (0.61) | GBA1ALDH1A1LMNAHRH4 | |
| SCHEMBL3410886 | 0.77 | CRHBP (0.64) | GBA1ALDH1A1LMNAHRH4 | |
| SCHEMBL31647387 | 0.77 | MAPT (0.67) | ALDH1A1LMNA | |
| SCHEMBL21815386 | 0.76 | GBA1 (0.51) | GBA1ALDH1A1LMNA | |
| SCHEMBL16795197 | 0.76 | PHGDH (0.44) | GBA1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270737-A1 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | STINGINN INC. (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4351578-A1 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | Stinginn Inc (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022245986-A1 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | STINGINN INC (US) | 2022-11-24 | — | — | WO | disclosed |
| EP-3856737-A1 | HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020064792-A1 | HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-04-02 | — | — | WO | disclosed |
| EP-3283472-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | Indiana University Research&Technology Corporation (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168619-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270737-A1 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | STING1, IRF3, MAVS | GBA1 2243/4885ALDH1A1 4812/4885LMNA 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.